Clinical trial · no report yet · Phase 1
NCT05358639
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
- NCT05358639 ↗
- Active, not recruiting
- Sunnybrook Health Sciences Centre
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 67 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase I Trial of the Combination of Olaparib and Navitoclax in Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian Cancer
- Interventions
- Olaparib tablet; Navitoclax
- Arms
- Single · Experimental
- Enrollment
- 36 (estimated)
- Primary outcomes
- To define a dose and schedule of navitoclax (Recommended Phase II Dose, RP2D) that can be combined safely with Olaparib in women with metastatic recurrent high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) for further study
- Sponsor
- Sunnybrook Health Sciences Centre with Exactis Innovation, Centre hospitalier de l'Université de Montréal (CHUM), Princess Margaret Hospital, Canada
- Start
- Nov 9, 2022
- Primary completion
- Mar 30, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05358639 · updated Nov 18, 2024